Select Page

References

New York Gastroenterology Associates participates in clinical research trials to offer our patients more treatment options for their conditions, as well as to contribute to the knowledge and practice of Gastroenterology. Please see below the trials at NYGA that we are participating in. If you are interested in learning more about these trials, please contact our research coordinator Salitah Qureshi at 347-248-8719 or Salitah.qureshi@nyga.md.

Filter by Reference Type

Filter by Condition

Filter by Doctor

BT-11-202B (Landos Biopharma)
Omilancor (BT-11) vs. Humira (Adalimumab)

Study Drug administration: Oral and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease
Inclusion criteria: endoscopically and clinically active CD, failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve
Exclusion criteria: abscesses, bowel resection or diversion within 6 months, positive for C. Difficile in past 4 months, HIV, Hepatitis B or Hepatitis C
Status: Enrolling

NX-13-1B (Landos Biopharma)
NX-13

Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Active Ulcerative Colitis
Inclusion criteria: endoscopically and clinically active UC, failed biologics or Biologic naïve (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)
Exclusion criteria: use of immunosuppressant (6-MP, azathioprine, methotrexate) within 25 days, treatment with Tofacitinib (Xeljanz) within 4 weeks, positive for C Difficile, Hepatitis B or C, HIV, surgical procedure requiring general anesthesia within 1 month or planned elective surgery, positive COVID-19 test within the past 6 months
Status: Enrolling

Request Your Appointment Today